Breaking tolerance: autoantibodies can target protein posttranslational modifications

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Autoantibodies (AAb) represent a promising avenue for cancer detection and therapeutic strategies.
• Understanding the specific self-epitopes targeted by AAb in tumors, but not normal tissues, is crucial for clinical translation.
• Posttranslational modifications (PTMs) on self-proteins are implicated in breaking immune tolerance in autoimmune diseases and cancer.

Purpose of the Study:

• To review existing high-throughput platforms for AAb detection.
• To discuss methods for characterizing immunogenic PTMs.
• To identify challenges in discovering disease-relevant autoantigens and propose solutions using future technologies.

Main Methods:

• Discussion of current high-throughput platforms for autoantibody detection.
• Review of methods for characterizing posttranslational modifications.
• Analysis of challenges in identifying cancer-specific autoantigens.

Main Results:

• Existing high-throughput platforms have limitations in detecting autoantibodies.
• Characterizing immunogenic PTMs requires advanced methodologies.
• Identifying disease-relevant antigens faces significant hurdles.

Conclusions:

• Exploiting the immune system's self/non-self discrimination offers great potential for antibody-based cancer diagnostics and therapeutics.
• Development of novel high-dimensional, high-throughput technologies is essential for advancing autoantigen discovery.
• Bridging the gap between basic immunology and clinical application requires technological innovation.